Compare Cytokinetics Inc (CYTK) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Prudential Financial Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Prudential Financial Inc trades at $111.8 (market cap $39.17B). The key difference: Prudential Financial Inc is far larger — about 4.5× Cytokinetics Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Prudential Financial Inc for 145 Days on average.
| CYTK | PRU | |
|---|---|---|
Market Cap | $8.62B | $39.17B |
Volume | 2,594,626 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $87.26 | $125.13 |
52-Week Low | $54.76 | $92.00 |
Typical Hold Time | 19 Days | 145 Days |
Enterprise Value | $8.72B | $67.95B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Prudential Financial (PRU) trades at $112.36, down 1.04% with a bearish technical outlook. The stock shows attractive valuation metrics including a P/E of 10.19 and P/S of 0.61, while recent earnings beat expectations in two of the last three quarters. The company is executing a strategic overhaul including a $3 billion capital rotation plan and emerging market exits, while benefiting from higher interest rates that boost investment income.
PRU presents a value opportunity with strong fundamentals but faces near-term technical pressure. The 67.57% analyst hold rating reflects cautious optimism, with the current price above the $105.67 consensus target. Key risks include execution of strategic initiatives and annuity market competition, while higher rates provide tailwinds for insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
